# Abbott Closes $21 Billion Acquisition of Exact Sciences, Creating Cancer Diagnostics Powerhouse

*2026-03-22 02:02 UTC · Business · 1 min read*

> Abbott will close its $21 billion acquisition of cancer diagnostics maker Exact Sciences on March 23, gaining control of the Cologuard test and other cancer screening technologies.

Abbott Laboratories will complete its $21 billion acquisition of Exact Sciences on March 23, after receiving all necessary regulatory clearances. Exact Sciences shareholders will receive $105 per share in cash, with the total enterprise value reaching approximately $23 billion including $1.8 billion in net debt.

The deal gives Abbott control of Exact Sciences' flagship Cologuard colorectal cancer screening test, as well as Oncotype Dx for breast cancer prognosis, CancerGuard for multi-cancer early detection, and Oncodetect for molecular residual disease monitoring. The acquisition is expected to add roughly $3 billion in incremental sales in 2026 and increase Abbott's annual growth by approximately 0.5%.

The transaction marks one of the largest life sciences deals in recent years and signals intensifying competition among major diagnostics companies to dominate the rapidly growing cancer testing market, particularly in multi-cancer early detection and precision oncology.

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/abbott-acquisition-of-exact-sciences-set-to-close-on-march-23-2026-302719347.html)
- [modernhealthcare.com](https://www.modernhealthcare.com/medical-devices/mh-abbott-laboratories-exact-sciences-acquisition-closed/)

---
TechTools News · https://techtools.cz/tools/news/article/959-abbott-closes-21-billion-acquisition-of-exact-sciences-creating-cancer
Česká verze: https://techtools.cz/tools/news/clanek/992-abbott-dokoncuje-akvizici-exact-sciences-za-21-miliard-dolaru-a-vytvari-lidra-v
